{"entity":{"id":"nct07623577","kind":"trial","name":"Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases","aka":[],"tldr":"A phase 2 trial of sacituzumab tirumotecan and bevacizumab in triple-negative breast cancer, run by Fudan University, now recruiting.","summary":"Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases is a phase 2, interventional study registered as NCT07623577 by Fudan University, with a registry enrolment figure of 24 participants, started 2026-01-01 and due to reach its primary completion in 2027-01. Interventions recorded: Sacituzumab Tirumotecan (Sac-TMT); bevacizumab. Conditions listed: TNBC; Brain Metastasis. Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07623577","url":"https://clinicaltrials.gov/study/NCT07623577"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early","brain-metastases"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["sacituzumab-tirumotecan","bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07623577","phase":"2","setting":"An Open-label, Single-arm, Multi-center Phase II Study of Sacituzumab Tirumotecan (Sac-TMT) Combined With Bevacizumab in Triple-negative Breast Cancer Patients With Brain Metastases","sponsor":"Fudan University","enrolled":24,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07623577/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"term":[{"id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/"},{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}]}}